Logo image of OCGN

OCUGEN INC (OCGN) Stock Fundamental Analysis

USA - NASDAQ:OCGN - US67577C1053 - Common Stock

1.61 USD
+0.08 (+5.23%)
Last: 10/24/2025, 8:00:02 PM
1.62 USD
+0.01 (+0.62%)
After Hours: 10/24/2025, 8:00:02 PM
Fundamental Rating

1

Taking everything into account, OCGN scores 1 out of 10 in our fundamental rating. OCGN was compared to 534 industry peers in the Biotechnology industry. OCGN may be in some trouble as it scores bad on both profitability and health. OCGN does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year OCGN has reported negative net income.
OCGN had a negative operating cash flow in the past year.
In the past 5 years OCGN always reported negative net income.
OCGN had a negative operating cash flow in each of the past 5 years.
OCGN Yearly Net Income VS EBIT VS OCF VS FCFOCGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

OCGN's Return On Assets of -106.24% is on the low side compared to the rest of the industry. OCGN is outperformed by 76.97% of its industry peers.
Looking at the Return On Equity, with a value of -1865.63%, OCGN is doing worse than 82.77% of the companies in the same industry.
Industry RankSector Rank
ROA -106.24%
ROE -1865.63%
ROIC N/A
ROA(3y)-79.4%
ROA(5y)-83.76%
ROE(3y)-144.88%
ROE(5y)-130.94%
ROIC(3y)N/A
ROIC(5y)N/A
OCGN Yearly ROA, ROE, ROICOCGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K

1.3 Margins

OCGN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OCGN Yearly Profit, Operating, Gross MarginsOCGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20K -40K -60K -80K

More info and screens

1

2. Health

2.1 Basic Checks

OCGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, OCGN has more shares outstanding
OCGN has more shares outstanding than it did 5 years ago.
OCGN has a worse debt/assets ratio than last year.
OCGN Yearly Shares OutstandingOCGN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
OCGN Yearly Total Debt VS Total AssetsOCGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

OCGN has an Altman-Z score of -6.99. This is a bad value and indicates that OCGN is not financially healthy and even has some risk of bankruptcy.
OCGN has a worse Altman-Z score (-6.99) than 67.42% of its industry peers.
A Debt/Equity ratio of 9.18 is on the high side and indicates that OCGN has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 9.18, OCGN is doing worse than 82.96% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 9.18
Debt/FCF N/A
Altman-Z -6.99
ROIC/WACCN/A
WACC9.32%
OCGN Yearly LT Debt VS Equity VS FCFOCGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

2.3 Liquidity

A Current Ratio of 1.83 indicates that OCGN should not have too much problems paying its short term obligations.
OCGN has a worse Current ratio (1.83) than 78.09% of its industry peers.
A Quick Ratio of 1.83 indicates that OCGN should not have too much problems paying its short term obligations.
OCGN has a worse Quick ratio (1.83) than 76.40% of its industry peers.
Industry RankSector Rank
Current Ratio 1.83
Quick Ratio 1.83
OCGN Yearly Current Assets VS Current LiabilitesOCGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

3

3. Growth

3.1 Past

OCGN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -11.11%.
Looking at the last year, OCGN shows a very negative growth in Revenue. The Revenue has decreased by -48.35% in the last year.
EPS 1Y (TTM)-11.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25%
Revenue 1Y (TTM)-48.35%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%20.33%

3.2 Future

OCGN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 51.82% yearly.
The Revenue is expected to grow by 203.55% on average over the next years. This is a very strong growth
EPS Next Y-14.08%
EPS Next 2Y-15.27%
EPS Next 3Y22.52%
EPS Next 5Y51.82%
Revenue Next Year-3.28%
Revenue Next 2Y-22.64%
Revenue Next 3Y209.94%
Revenue Next 5Y203.55%

3.3 Evolution

OCGN Yearly Revenue VS EstimatesOCGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B
OCGN Yearly EPS VS EstimatesOCGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -50 -100 -150

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

OCGN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year OCGN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OCGN Price Earnings VS Forward Price EarningsOCGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OCGN Per share dataOCGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.05 -0.1 -0.15 -0.2 -0.25

4.3 Compensation for Growth

OCGN's earnings are expected to grow with 22.52% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-15.27%
EPS Next 3Y22.52%

More info and screens

0

5. Dividend

5.1 Amount

OCGN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

OCUGEN INC

NASDAQ:OCGN (10/24/2025, 8:00:02 PM)

After market: 1.62 +0.01 (+0.62%)

1.61

+0.08 (+5.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-01 2025-08-01/bmo
Earnings (Next)11-05 2025-11-05
Inst Owners16.63%
Inst Owner Change-0.03%
Ins Owners1.12%
Ins Owner Change0%
Market Cap502.80M
Revenue(TTM)4.75M
Net Income(TTM)-56939000
Analysts82
Price Target6.63 (311.8%)
Short Float %17.16%
Short Ratio10.57
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.75%
Min EPS beat(2)14.75%
Max EPS beat(2)14.75%
EPS beat(4)4
Avg EPS beat(4)11.05%
Min EPS beat(4)6.63%
Max EPS beat(4)14.75%
EPS beat(8)8
Avg EPS beat(8)20.5%
EPS beat(12)10
Avg EPS beat(12)16.15%
EPS beat(16)10
Avg EPS beat(16)-204.99%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)2.61%
EPS NQ rev (3m)6.67%
EPS NY rev (1m)6.25%
EPS NY rev (3m)7.61%
Revenue NQ rev (1m)37.5%
Revenue NQ rev (3m)83.33%
Revenue NY rev (1m)0%
Revenue NY rev (3m)39.21%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 105.76
P/FCF N/A
P/OCF N/A
P/B 164.75
P/tB 164.75
EV/EBITDA N/A
EPS(TTM)-0.2
EYN/A
EPS(NY)-0.25
Fwd EYN/A
FCF(TTM)-0.17
FCFYN/A
OCF(TTM)-0.17
OCFYN/A
SpS0.02
BVpS0.01
TBVpS0.01
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -106.24%
ROE -1865.63%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-79.4%
ROA(5y)-83.76%
ROE(3y)-144.88%
ROE(5y)-130.94%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 9.18
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 19%
Cap/Sales 12.18%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.83
Quick Ratio 1.83
Altman-Z -6.99
F-Score3
WACC9.32%
ROIC/WACCN/A
Cap/Depr(3y)863.08%
Cap/Depr(5y)672.89%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-11.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25%
EPS Next Y-14.08%
EPS Next 2Y-15.27%
EPS Next 3Y22.52%
EPS Next 5Y51.82%
Revenue 1Y (TTM)-48.35%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%20.33%
Revenue Next Year-3.28%
Revenue Next 2Y-22.64%
Revenue Next 3Y209.94%
Revenue Next 5Y203.55%
EBIT growth 1Y13.35%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y30.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y24.24%
OCF growth 3YN/A
OCF growth 5YN/A

OCUGEN INC / OCGN FAQ

What is the fundamental rating for OCGN stock?

ChartMill assigns a fundamental rating of 1 / 10 to OCGN.


What is the valuation status of OCUGEN INC (OCGN) stock?

ChartMill assigns a valuation rating of 1 / 10 to OCUGEN INC (OCGN). This can be considered as Overvalued.


What is the profitability of OCGN stock?

OCUGEN INC (OCGN) has a profitability rating of 0 / 10.


Can you provide the financial health for OCGN stock?

The financial health rating of OCUGEN INC (OCGN) is 1 / 10.


Can you provide the expected EPS growth for OCGN stock?

The Earnings per Share (EPS) of OCUGEN INC (OCGN) is expected to decline by -14.08% in the next year.